Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • TRACK A – Basic Science
  • TRACK B – Clinical Science
  • TRACK C – Prevention Science
  • TRACK D – Implementation Science

HIV Evolution and Phylodynamics (Intra- and Inter-Host)

A1 Viral origins, evolution and diversity
A2 Viral fitness and resistance


A3 Entry (attachment, receptors and co-receptors, penetration and tropism)
A4 Viral replicative cycle (reverse transcription, integration, viral assembly and maturation)
A5 Transcriptional and gene expression regulation (including regulatory genes)

Immune Responses (Innate and Adaptive)

A6 Innate immunity
A7 Humoural immunity
A8 Cellular immunity
A9 Mucosal immunity
A10 Virus escape from adaptive immunity

Pathogenesis (Immune Function and Dysfunction)

A11 Systemic immune activation and inflammation
A12 T cell depletion and reconstitution, and immune ageing
A13 Microbiomes and microbial translocation
A14 Latency and viral reservoirs
A15 Correlates of HIV susceptibility and disease progression (biomarkers and genetics)
A16 HIV co-morbidities
A17 Systems biology approaches to HIV infection

Natural Protection against HIV/AIDS

A18 HIV controllers (including post-treatment controllers) and long term non-progressors
A19 Highly exposed seronegative individuals (HESN)
A20 Correlates of immune protection

Transmission and Early Infection

A21 Mucosal transmission
A22 Vertical transmission
A23 Blood borne transmission
A24 Founder viruses/transmission bottleneck
A25 Acute and early infection

Novel Treatment, Prevention and Cure Strategies

A26 Preclinical drug development, including prophylactic drug and microbicide development
A27 Nucleic acid-based HIV therapies
A28 Targeting HIV persistence during ART (cure strategies)
A29 Immunotherapy

Vaccine Development

A30 Cell-based preventative vaccines
A31 Adjuvants
A32 Novel vectors and strategies
A33 Therapeutic vaccines

Super- and Co-Infections (Including Opportunistic Infections)

A34 HIV-1 super-infection/inter/intra subtype co-infection
A35 HIV-2
A36 Viral hepatitis
A37 Mycobacteria and tuberculosis
A38 Other pathogens

Diagnostic Tools for Immunological and Virological Monitoring of HIV Infection

A39 Novel assays of immune responses
A40 Novel approaches to assess viral load and ARV resistance/tropism

Animal Models (Excluding Latency/Reservoirs)

A41 Viral determinants of SIV pathogenesis
A42 Animal models of transmission, disease progression and spontaneous control
A43 Novel animal/virus models for vaccine, cure research and inhibitor development

Course of HIV Disease

B1 Disease progression
B2 Acute and early infection (including treatment)
B3 Long-term non-progressors and elite controllers
B4 HIV-2
B5 Gender differences in HIV

Diagnostic and Monitoring Tools

B6 HIV testing
B7 CD4 measurement (including point of care diagnostics)
B8 Long-term non-progressors and elite controllers
B9 Viral load measurement (including point of care diagnostics)
B10 Measuring ART adherence (drug levels, dried blood spots, hair sampling)
B11 Drug resistance testing
B12 Diagnostics of co-infections and comorbidities

Co-Infections (Including Opportunistic Infections)

B13 Opportunistic infections (excluding TB)
B14 Tuberculosis and other mycobacteria
B15 Other bacterial, viral and parasitic infections
B16 Viral hepatitis
B17 Human papillomavirus
B18 Syphilis and other STI’s

Comorbidities and Complications (Including those Related to ART)

B19 Neurologic disorders
B20 Depression and other psychiatric manifestations
B20 Depression and other psychiatric manifestations
B21 AIDS and non-AIDS malignancies
B22 Lipodystrophy and hyperlipidaemia
B23 Cardiovascular disease
B24 Bone disease
B25 Renal disease
B26 Metabolic, lipid and endocrine complications, obesity
B27 Hepatic complications (including NASH)
B28 Ageing with HIV (including polypharmacy and frailty)
B29 Immune reconstitution disorders / immune reconstitution inflammatory syndrome (IRIS)
B30 Other ART complications and adverse reactions
B31 Biomarkers for the prediction of morbidity and mortality
B32 Scaling up NCD screening and treatment (clinical aspects)
B33 Strategies for promoting long-term health

Antiretroviral Therapies in Adults (Clinical Trials and Observational Cohort Studies)

B34 ART in first- and second-line therapies
B35 ART in highly treatment-experienced persons
B36 ART in highly treatment-experienced persons
B35 Management of late presenters
B37 Regimen simplification and switch studies
B38 Pharmacology / pharmacokinetics / pharmacogenomics / role of therapeutic drug monitoring
B39 Drug interactions
B40 Antiretroviral drug resistance
B41 Long-acting agents
B42 ARVs and HIV reservoirs/immunity relevant to HIV remission and cure
B43 Ethical issues in clinical trials and treatment strategies

Other Strategies and Therapies (non-ART)

B44 Therapeutic vaccine trials
B45 Other immune-based therapy trials
B46 Complementary and traditional medicines
B47 Cure interventions (including those aimed at reservoir depletion)
B48 Novel therapeutic approaches (including gene therapy)
B49 Pain and palliative medicine
B50 Nutrition

Clinical Issues Specific to Women

B51 Clinical management issues and pharmacokinetics during and after pregnancy
B52 Safe conception for serodiscordant couples
B53 Menopause and HIV
B54 Contraception and HIV
B55 Gender specific issues of ART efficacy, adverse reactions and complications

Clinical Issues Specific to Paediatric and Adolescent HIV

B56 Diagnosis of HIV disease in paediatric populations
B57 Engagement and linkage to care in paediatric and adolescent HIV
B58 Pharmacokinetics / pharmacodynamics / pharmacogenomics in paediatric populations
B59 Therapeutic drug monitoring in paediatric population
B60 Drug formulations for infants and children
B61 Clinical trials in children and adolescents
B62 Adherence in paediatric and adolescent populations
B63 HIV complications and comorbidities in children and adolescents
B64 Opportunistic infections in paediatric and adolescent populations
B65 HIV-exposed uninfected children
B66 ARV management strategies in paediatric and adolescent populations
B67 Behavioural health outcomes in children and adolescents
B68 Mental health and neuro-cognition in paediatric and adolescent populations
B69 HIV-associated co-infections and malignancies in paediatric and adolescent populations
B70 Transition of adolescents into adult care

Clinical Issues Specific to Key Populations

B71 Clinical issues in men who have sex with men
B72 Clinical issues in people who use drugs
B73 Clinical issues in sex workers
B74 Clinical issues in transgender and non-binary populations (including access to gender affirming care)
B75 Clinical issues in other key populations

Epidemiology of HIV

C1 Natural history, progression and survival
C2 Measurement and modelling of the HIV epidemics
C3 Risk factors for acquisition, infectivity, progression and transmission of HIV
C4 Network studies of risk behaviours and their implications for prevention
C5 Epidemiology of HIV in key populations (MSM, transgender, migrants, serodiscordant couples)
C6 Epidemiology of opportunistic infections and co-infections
C7 Epidemiology of serious non-AIDS events
C8 Epidemiology of AIDS defining and non-AIDS defining cancers and other comorbidities
C9 Molecular epidemiology
C10 Determination of HIV incidence
C11 Diagnosis of HIV infection (detection of acute and recent HIV infection, including self-testing)
C12 Surveillance of HIV and HIV drug resistance
C13 Surveillance systems and methods, including geographical information systems
C14 Population-based surveys with HIV testing and viral load in epidemiology studies
C15 Measurement of behaviours and adherence, including biomedical measures (including biomedical devices and bioassays)
C16 Measurement and modelling of the impact of prevention and treatment interventions

Approaches and Tools for HIV Prevention

C17 STI control to prevent HIV transmission
C18 Male and female condoms and other physical barriers
C19 Male circumcision
C20 PEP, PrEP (long-acting and oral) and microbicides
C21 Treatment as prevention
C22 Vaccines (both passive and active)
C23 Adherence to HIV prevention strategies
C24 Strategies for identifying key populations
C25 Use of the internet, social media, mobile phones and other e-devices for prevention
C26 Integration of HIV prevention services into health and other platforms
C27 Combination prevention approaches
C28 Participatory practice and community involvement in prevention research
C29 Study designs in prevention research
C30 Ethical and human rights issues in epidemiological, prevention and other research
C31 Behavioural interventions to prevent HIV transmission

Prevention of Mother to Child Transmission

C32 Reducing pre-partum and intra-partum transmission to infants
C33 Reducing post-partum transmission in infants
C34 Strategies to increase HIV testing in pregnant women and mothers and their partners
C35 PMTCT services for marginalized populations
C36 Integration of family planning and HIV services, including coverage and quality of PMTCT programmes)
C37 Promoting health and reducing maternal mortality in HIV-positive women

Population-Specific Interventions and HIV Prevention Strategies

C38 Prevention of vertical transmission (including in key and other vulnerable populations)
C39 Prevention for HIV serodiscordant couples
C40 Prevention for populations with multiple co-occurring epidemics
C41 Prevention during acute and recent infection
C42 Prevention among HIV-infected individuals
C43 Prevention in health care and other institutional settings
C44 Prevention addressing gender inequalities
C45 Prevention of TB among people living with HIV
C46 Prevention of HIV infection in IVDU

Feasibility and Impact of Structural Interventions

C47 Assessing impact/cost-effectiveness of structural interventions and social protection
C48 Gender sensitization, empowerment and violence reduction
C49 Collectivization, mobilization, stigma reduction programmes
C50 Policy-level HIV interventions including legal-policy reform

Infrastructure and Delivery Models for the Scale Up of HIV Services

D1 Methodological challenges to scale up and optimization of services
D2 Impact evaluation of different models of service delivery
D3 Provider and facility determinants of outcomes
D4 Methods to improve provider quality, supply and tailoring of services
D5 Healthcare workers and volunteers: training, mentoring, retaining, task shifting, safety
D6 Demand generation for HIV services
D7 Models of public-private partnerships

Strategies to Increase Uptake of and Retention in HIV Services

D8 Operational challenges in implementing HIV services
D9 Socio-economic challenges in implementing HIV services
D10 Adherence to HIV treatment
D11 Uptake of HIV services
D12 Retention in HIV services
D13 Linkage between HIV services
D14 Indicators of quality of care
D15 Differentiated models of care
D16 Use of financial incentives/behavioural economics
D17 Combination interventions that span prevention / screening / treatment

Integration of HIV Services with Other Programmes

D18 Integration of HIV services with other health programmes
D19 Integration of HIV and HCV services
D20 Integration of HIV services with other development programmes
D21 Integration of prevention interventions with care/treatment


D22 Scale up of paediatric diagnosis
D23 Scale up of point-of-care technologies
D24 Scale up of viral load monitoring
D25 Optimal split between laboratory-based and point-of-care devices

Sustainable Financing

D26 National and international financing initiatives
D27 Transitional financing
D28 Impact of donor agencies' policies
D29 Impact of financial crises
D30 Leveraging HIV funding to strengthen health systems beyond HIV programmes
D31 Building country ownership in HIV programming

Health Systems Strengthening

D32 Changes in policy and practice
D33 Capacity building initiatives
D34 Translation, incorporation and use of key IR findings into programmes and practice

Monitoring and Evaluation

D35 Monitoring and evaluation of prevention
D36 Monitoring and evaluation of testing
D37 Monitoring and evaluation of treatment and care
D38 Monitoring and evaluation of HIV cascade
D39 Monitoring and evaluation of health systems